

9th May 2019

Mr. Eben Booyens

[...]

[...]

[...]

[...]

Dear Mr. Booyens

ANTI-DOPING RULE VIOLATION: CONSEQUENCES: WRITTEN DECISION

Introduction

1. Our previous letter and notice dated 8th April 2019 refers. The South African Institute for Drug Free Sport (SAIDS) and all participants in sport are required to act in accordance with the South African Institute for Drug Free Sport Anti-Doping Rules 2016 (“the Rules”).
2. You have been notified of an Anti-Doping Rule Violation in terms of Article 2.1 of the Rules for the presence of Drostanolone M1(2 α -methyl-5 α -androstan-3 α -ol-17-one), a metabolite of Drostanolone in your A sample (sample number 4341791) collected on the 29th April 2018.
3. You did not request to have your B sample analysed. Furthermore, we received correspondence from you dated 7th May 2019 where you do not dispute the adverse analytical finding, acknowledged the presence of Drostanolone M1(2 α -methyl-5 α -androstan-3 α -ol-17-one), a metabolite of Drostanolone, and accepted the consequences of your actions.

BOARD MEMBERS: JUDGE L. MPATI (CHAIRPERSON), MR. G. ABRAHAMS, DR. H. ADAMS, MR. D. BAYEVER, DR. S. MANJRA, DR. M. PEENZE, DR. M. QOBOSE, MR. M. QUINN, PROF. L. SKAAL, DR. P. ZONDI, MR. K. GALANT (CEO)



4. SAIDS is required, in circumstances where there is no dispute¹:-
 - a. To issue a written decision confirming the commission of the Anti-Doping Rule Violation and the Consequences imposed.
 - b. To set out the reasons for the period of Ineligibility imposed and (if applicable) a justification as to why the maximum period of Ineligibility was not imposed.
 - c. To send copies of the decision to other Organisations, viz. South African Powerlifting Federation (SAPF), International Powerlifting Federation (IPF) and the World Anti-Doping Agency (WADA) with a right of appeal and to make Public Disclosure.

5. SAIDS has assessed the facts of your case, has arrived at a decision, and this letter sets out that decision and the reasons it has been arrived at.

The Anti-Doping Rule Violation

6. You have committed and are guilty of the Anti-Doping Rule Violation referred to above. In other words of the Anti-Doping Rule Violation set out in point 2.

Consequences

7. The Consequences that the Rules contemplate distinguish between Prohibited Substances that are Specified Substances and those that are not. The Consequences for the use of Prohibited Substances that are not Specified will in most instances include a four (4) year period of ineligibility. Where a substance is Specified the athlete can also be ineligible for such a period if SAIDS demonstrates that the Anti-Doping Rule Violation was intentional.

8. Where SAIDS does not demonstrate intentional use then the period of ineligibility the Rules provide for is two (2) years. The period of two (2) years can be reduced in certain specified circumstances which require you to show that you bore no significant fault or negligence here.

¹ Article Rule 7.10.3 of the Rules

9. SAIDS considers that in these circumstances the appropriate Consequences should be a period of *Ineligibility* of four (4) Years. You were provisionally suspended and co-operated with SAIDS. Therefore your period of suspension would be effective as from the date of sample collection of the adverse analytical finding, being 23rd February 2019.
10. The reasons for the imposition of these Consequences are that: -
- The substances in question Drostanolone M1(2 α -methyl-5 α -androstan-3 α -ol-17-one), a metabolite of Drostanolone is not a Specified Substance;
 - SAIDS is not required, in the circumstances, to prove anything more than presence and no factors have been advanced by you that would suggest there is a basis for further reducing the period of ineligibility and doing so would be unfairly discriminatory towards other athletes;
 - There is no basis for SAIDS to conclude that you were not negligent in these circumstances.

Sanction Period

11. The period of ineligibility will be applicable as of 23rd February 2019 until and including 22nd February 2023.

Yours faithfully



**Wafeekah Begg
(Legal Manager)**

BOARD MEMBERS: JUDGE L. MPATI (CHAIRPERSON), MR. G. ABRAHAMS, DR. H. ADAMS, MR. D. BAYEVER,
DR. S. MANJRA, DR. M. PEENZE, DR. M. QOBOSE, MR. M. QUINN, PROF. L. SKAAL, DR. P. ZONDI, MR. K. GALANT (CEO)



